Chronic hepatitis C virus infection in older adults

Clinical Infectious Diseases

Volumn 41, Issue 11, 2005, Pages 1606-1612

  Marcus, Esther Lee ^a,d   Tur Kaspa, Ran ^b,c  

^a HEBREW UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d HERZOG HOSPITAL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYTOCHROME P450 1A2; PEGINTERFERON ALPHA2A; PROTEINASE INHIBITOR; RIBAMIDINE; RIBAVIRIN; VIRUS RNA;

ADULT; AGE; AGED; DISEASE COURSE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INFECTION RATE; INFECTION RISK; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEROPREVALENCE;

AGING; ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; PREVALENCE; UNITED STATES;

EID: 28044472960     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/497597     Document Type: Review

References (63)

1. Armstrong GL, Simard EP, Wasley A, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus (HCV) infection in the United States 1999-2002 [abstract 31]. Hepatology 2004; 40(Suppl 1): 176A.
2. McHutchison JG. Understanding hepatitis C. Am J Manag Care 2004; 10(2 Suppl):S21-9.
3. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-62.
4. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31:777-82.
5. Okayama A, Stuver SO, Tabor E, et al. Incident hepatitis C virus infection in a community-based population in Japan. J Viral Hepat 2002; 9:43-51.
6. Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997; 26:1006-11.
7. Chien NT, Dundoo G, Horani MH, Osmack P, Morley JH, Di Bisceglie AM. Seroprevalence of viral hepatitis in an older nursing home population. J Am Geriatr Soc 1999; 47:1110-3.
8. Marcus EL, Dahoudi N, Tur-Kaspa R. Hepatitis C virus infection among elderly patients in a geriatric hospital. Arch Gerontol Geriatr 1994; 19:213-21.
9. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36(Suppl 1):S35-46.
10. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C infection. Hepatology 2001; 34:809-16.
11. Watson JP, Brind AM, Chapman CE, et al. Hepatitis C virus: epidemiology, and genotypes in the north east of England. Gut 1996; 38: 269-76.
12. Minola E, Prati D, Suter F, et al. Age of infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 2002; 99: 4588-91.
13. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332:1463-6.
14. Ben Yehuda A, Globerson A, Krichevsky S, et al. Ageing and the mismatch repair system. Mech Ageing Dev 2000; 121:173-9.
15. Ohishi W, Kitamoto M, Aikata H, et al. Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan. Scand J Gastroenterol 2003; 38:894-900.
16. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. American Association for the Study of Liver Diseases. Hepatology 2004; 39:1147-71.
17. Trevisani F, Cantarini MC, Labate AM, et al. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol 2004; 99: 1470-6.
18. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34:730-9.
19. Horiike N, Masumoto T, Nakanishi K, et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 1995; 10:246-9.
20. Kao JH, Lai MY, Chen PJ, Hwang LH, Chen W, Chen DS. Clinical significance of serum hepatitis C virus titers in patients with chronic type C hepatitis. Am J Gastroenterol 1996; 91:506-10.
21. Wali M, Harrison RP, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51:248-52.
22. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41:830-6.
23. Ratziu V, Dargere D, Conti M, et al. Increased fibrotic response in the ageing liver [abstract 570]. Hepatology 2000; 32(4 Pt 2):302A.
24. Thabut D, Calvez SL, Thibault V, et al. Hepatitis C in 2410 patients 65 years or older: a severe and neglected curable disease [abstract 549]? Hepatology 2003; 38(Suppl 1):424A.
25. Monica F, Lirussi F, Nassuato G, Castelletto MR, Mottola A, Okolicsanyi L. Hepatitis C virus infection and related chronic liver disease in a resident elderly population: the Silea Study. J Viral Hepat 1998; 5:345-51.
26. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33:455-63.
27. Poynard T, Cacoub P, Ratziu V, et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat 2002; 9:295-303.
28. Hassoun Z, Willems B, Deslauriers J, Nguyen BN, Huet PM. Assessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact Scale. Dig Dis Sci 2002; 47:2674-81.
29. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35:433-9.
30. Chang KM. Immunopathogensis of hepatitis C virus infection. Clin Liver Dis 2003; 7:89-105.
31. Pawelec G, Barnett Y, Forsey R, et al. T cells and aging, January 2002 update. Front Biosci 2002; 7:d1056-183.
32. Effros RB. Replicative senescence of CD8 T cells: effect on human ageing. Exp Gerontol 2004; 39:517-24.
33. + T cells in humans: a contribution to understand the relationship between inflammation and immunosenescence. Exp Gerontol 2003; 38:981-7.
34. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 2000; 51:245-70.
35. Foster GR. Past, present, and future hepatitis C treatments. Semin Liver Dis 2004; 24(Suppl 2):97-104.
36. Rebetol (Ribavirin, USP) capsules product information. Available at: http://www.fda.gov/medwatch/SAFETY/2003/03May_PI/Rebetol_PI .pdf. Accessed 13 May 2005.
37. Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis? Expert Rev Mol Diagn 2005;5:15-21.
38. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-50.
39. Poordad FF. FIBROSpect II: a potential noninvasive test to assess hepatic fibrosis. Expert Rev Mol Diagn 2004; 4:593-7.
40. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon α-2b and ribavirin. Hepatology 2003; 38: 481-92.
41. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C: the METAVIR Cooperative Study Group. Hepatology 1996; 24:289-93.
42. Toyoda H, Kumada T, Kiriyama S, et al. Influence of age, sex, and degree of liver fibrosis on the association between serum alanine aminotransferase levels and liver inflammation in patients with chronic hepatitis C. Dig Dis Sci 2004; 49:295-9.
43. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.
44. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
45. Strader DB. Understudied populations with hepatitis C. Hepatology 2002; 36(Suppl 1):S226-36.
46. Marcus EL, Tur-Kaspa R. Viral hepatitis in older adults. J Am Geriatr Soc 1997; 45:755-63.
47. Bacosi M, Russo F, D'innocenzo S, et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatol Res 2002; 22:231-9.
48. Alessi N, Freni MA, Spadaro A, et al. Efficacy of interferon treatment (IFN) in elderly patients with chronic hepatitis C. Infez Med 2003; 11: 208-12.
49. Imai Y, Kasahara A, Tanaka H, et al. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. J Gastroenterol 2004; 39:1069-77.
50. Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142:105-14.
51. Nudo CG, Gupta S, Alpert E, Wong P, Hilzenrat N, Deschenes M. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C [abstract 48]. Can J Gastroenterol 2004; 18(Suppl A): 83A.
52. Arias E. United States life tables, 2002. Natl Vital Stat Rep 2004; 53: 1-38.
53. Gupta SK, Glue P, Jacobs S, Belle D, Affrime M. Single-dose pharmacokinetics and tolerability of pegylated interferon-α2b in young and elderly healthy subjects. Br J Clin Pharmacol 2003; 56:131-4.
54. Martin NE, Modi MW, Reddy KR. Characterization of pegylated (40 kDa) interferon α-2A (PEGASYS) in the elderly [abstract 755]. Hepatology 2000; 32(4 pt 2):348A.
55. Matthews SJ, McCoy C. Peginterferon α-2a: a review of approved and investigational uses. Clin Ther 2004; 26:991-1025.
56. Floreani A, Chiaramonte M. Hepatitis in nursing homes: incidence and management strategies. Drugs Aging 1994; 5:96-101.
57. Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-α therapy: a prospective study. Gen Hosp Psychiatry 2003; 25:34-8.
58. Baracskay D, Jarjoura D, Cugino A, Blend D, Rutecki GW, Whittier FC. Geriatric renal function: estimating glomerular filtration in an ambulatory elderly population. Clin Nephrol 1997; 47:222-8.
59. Takaki S, Tsubota A, Hosaka T, et al. Factors contributing to ribavirin dose reduction due to anemia during interferon α2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol 2004; 39: 668-73.
60. Noraura H, Tanimoto H, Kajiwara E, et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol 2004; 19:1312-7.
61. Gish RG, Arora S, Nelson D, et al. End-of-treatment (EOT) response in therapy-naive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon α-2a [abstract 519]. Hepatology 2004; 40(4 Suppl 1):388A.
62. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-9.
63. Dagan S, Eren R. Therapeutic antibodies against viral hepatitis. Curr Opin Mol Ther 2003; 5:148-55.